

Fig. 1 - grafts showing the association of the level of Bax and the ex-vivo response of CLL patients to a number of cytostatic agents. The figure shows the relative level of Bax protein expression (densitometric values from Western blot analyses) and the LC90 dose for each of the cytostatic agents;

A1 Fig. 2 - grafts showing the association between Bax expression and the LC90 dose of doxorubicin in 37 CLL patients. This relationship with regard to the cytotoxic effect of the cytostatic agent could only be observed for Bax, but not for Bcl-2 or the ratio of Bcl-2 to Bax;

Fig. 3 - grafts showing the reduced sensitivity to cytostatic agents (height of the bars corresponds to the dose of the cytostatic in $\mu\text{g/ml}$) for p53-mutant CLL patients compared to the p53 wild type. The p53 mutations were determined for the exons 5 to 8 using SSCP-PCR.

Detailed Description of the Preferred Embodiments -;

Page 11, please delete this page in its entirety.

IN THE CLAIMS

Please amend the claims in accordance with the attached marked-up pages. A clean copy of the amended claims is also enclosed.

REMARKS

The above amendments were made to place the application into proper United States Patent Format.

Respectfully Submitted,



Bruce S. Londa
Attorney for Applicant
Norris, McLaughlin & Marcus P.A.
220 East 42nd Street, 30th Floor
New York, N.Y. 10017
Telephone: (212) 808-0700
Telecopier: (212) 808-0844